Moderna gave investors a scare as its stock plunged on Thursday. But it's still one of the hottest biotechs this year. And it's hardly alone – the sector is on a roll and looks poised for more gains.

A study of a personalized vaccine combined with an existing immunotherapy found the treatment helped patients with melanoma avoid cancer recurrence. The combination trains the patient's immune system ...

Six melanoma specialists said the Moderna and Merck vaccine results represent a clinically meaningful advance in melanoma ...

The vaccine, called intismeran, is tailored to each patient’s tumour. The findings, which measured recurrence risk over two ...

Moderna and Merck stocks fell as new melanoma vaccine trial data showed a 42% recurrence reduction, missing investor ...

The data were not bad — in fact, the outcome was better than many analysts had predicted. The problem was Cambridge-based ...

A Moderna and Merck personalized mRNA cancer vaccine reduced the risk of disease recurrence in patients with melanoma by 42% ...

Pfizer's 5.7% dividend yield towers over Merck's, yet that gap may signal something retirees cannot afford to ignore. Before ...

In a study presented this week at the IDWeek 2026 conference in Washington, DC, a team of Indian researchers estimated that ...

Pfizer (NYSE:PFE) signed a new research collaboration and license agreement with Enodia Therapeutics to develop Sec61 ...

This is a repost of an article published on AnswersNews on May 18, 2026.An analysis of the performance of 26 pharmaceutical ...

MRNA expands beyond COVID-19 with new RSV, flu and combination vaccines, but fierce competition could challenge its efforts ...